Therapeutic Goods Act 1989 - Order under subsection 3(1) – Definition of British Pharmacopoeia (15/05/2006)

Overview

The Therapeutic Goods Act 1989 was enacted to establish and maintain a regulatory system ensuring the quality, safety, efficacy, and timely availability of therapeutic goods in Australia. Administered by the Therapeutic Goods Administration, the Act mandates that therapeutic goods, excluding medical devices, meet specified standards when imported, supplied for use, or exported from Australia. The British Pharmacopoeia (BP) serves as the principal standard for such goods, with its applicable edition determined by the Minister for Health and Ageing or their delegate. To maintain consistency with international standards, the definition of 'British Pharmacopoeia' was amended by order to align with the British Pharmacopoeia 2005, effective from 1 July 2006, following consultations with relevant industry associations and without any objections. This amendment, considered a routine procedure, does not substantially alter existing arrangements under the Act.

Scope and Application

The Therapeutic Goods Act 1989 (the Act) applies to the quality, safety, efficacy, and timely availability of therapeutic goods in Australia, including those exported from Australia. This legislation establishes a regulatory framework administered by the Therapeutic Goods Administration (TGA) to ensure that medicines and other therapeutic goods meet certain standards before they are imported into, supplied for use in, or exported from Australia. The Act applies to all therapeutic goods, except medical devices, and mandates that these goods comply with applicable standards, which are either specified in orders made under the Act or, in the absence of such orders, defined by the monographs in the British Pharmacopoeia. The British Pharmacopoeia (BP) is the principal standard for these goods. The Act allows the Minister for Health and Ageing to determine which edition of the BP applies, ensuring Australia's alignment with international standards for therapeutic goods quality and safety. The recent amendment, effective from 1 July 2006, updates the definition of the British Pharmacopoeia in the Act to British Pharmacopoeia 2005, following consultation with relevant industry stakeholders.

Key Provisions

The primary operative section of the legislation is subsection 3(1) of the Therapeutic Goods Act 1989, which originally defined 'British Pharmacopoeia' as the edition of the book in effect for the purposes of the Therapeutic Goods Act 1966 before the commencement of the current Act, including any subsequent amendments or new editions specified by the Minister. This definition allows the Minister or the delegate to determine which edition of the British Pharmacopoeia (BP) will apply. Effective from 1 July 2006, the Act now defines 'British Pharmacopoeia' as the British Pharmacopoeia 2005, ensuring that the latest edition is applied as the standard for therapeutic goods. Under this Act, medicines and other therapeutic goods that are not medical devices must comply with a standard applicable to the goods. The BP serves as the principal (or default) standard for these goods. Section 14 of the Act mandates that therapeutic goods imported into, supplied for use in, or exported from Australia must conform with a specified standard. For goods subject to a BP monograph, the standard is constituted by the statements in that monograph. This requirement ensures that the quality, safety, and efficacy of therapeutic goods are maintained in alignment with international standards. The Act imposes several obligations on the parties and entities it governs. Firstly, manufacturers, importers, and suppliers of therapeutic goods must ensure that their products conform to the standards specified in the BP. This includes adhering to the latest edition of the BP, which, as per the amendment, is the British Pharmacopoeia 2005. The Therapeutic Goods Administration (TGA) is responsible for administering the Act and ensuring compliance through monitoring and enforcement. Additionally, stakeholders, including industry associations and consumer advocates, are required to comply with the new definition, ensuring that their practices align with the updated standard. Any breach of the Act's provisions can lead to civil or criminal consequences. Under the Act, penalties for non-compliance can include fines and, in severe cases, imprisonment. For example, section 34(1) of the Act allows for a penalty of up to $22,200 for individuals and $111,000 for bodies corporate for each contravention. Moreover, section 34(2) provides for imprisonment for up to two years for serious or repeated contraventions. These penalties underscore the importance of adhering to the standards set forth in the Act to ensure the safety and quality of therapeutic goods in Australia.